Clinical Trial Update: A Multicentre Investigation of 2 Cycles Rituximab Compared With Standard Regimen in Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia （ITP） [Phase 3]

View source ↗

Summary

Phase 3 multicentre trial evaluating two cycles of rituximab vs standard regimen for steroid-resistant/relapsed immune thrombocytopenia was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: Shandong University | Conditions: Immune Thrombocytopenia | Phase 3 | Status: WITHDRAWN